Copyright (c) 2015 AJC
This work is licensed under a Creative Commons Attribution 4.0 International License.
Synthesis and Biological Evaluation of 1,2,3,4-Tetrahydroisoquinolines Derivatives as Monoamine Oxidase Inhibitors for Treatment of Alzheimer’s and Parkinson’s Diseases
Corresponding Author(s) : Yu Yu
Asian Journal of Chemistry,
Vol. 27 No. 10 (2015): Vol 27 Issue 10
Abstract
A series of 1,2,3,4-tetrahydroisoquinolines derivatives were synthesized and evaluated their inhibition effect on monoamine oxidase (MAO). The results of pharmacological test revealed that all the five compounds had certain monoamine oxidase inhibitory activity and compound 6h displayed preferable selective inhibition on MAO-A. These data suggested that newly synthesized 1,2,3,4-tetrahydroisoquinoline derivatives can be evaluated as monoamine oxidase inhibitors which may have promising features in the treatment of Alzheimer’s and Parkinson’s diseases.
Keywords
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
- J. Dingemanse, G. Zürcher and R. Kettler, Eur. J. Pharm. Sci., 12, 159 (2000); doi:10.1016/S0928-0987(00)00151-2.
- C. Binda, F. Hubálek, M. Li, D.E. Edmondson and A. Mattevi, FEBS Lett., 564, 225 (2004); doi:10.1016/S0014-5793(04)00209-1.
- J.C. Shih, K. Chen and M.J. Ridd, Ann. Rev. Neurosci., 22, 197 (1999); doi:10.1146/annurev.neuro.22.1.197.
- D.J. Moore, A.B. West, V.L. Dawson and T.M. Dawson, Ann. Rev. Neurosci., 28, 57 (2005); doi:10.1146/annurev.neuro.28.061604.135718.
- M. Bembenek, C.W. Abell, L.A. Chrisey, M.D. Rozwadowska, W. Gessner and A. Brossi, J. Med. Chem., 33, 147 (1990); doi:10.1021/jm00163a025.
- M.B.H. Youdim, A. Gross and J.P.M. Finberg, Br. J. Pharmacol., 132, 500 (2001); doi:10.1038/sj.bjp.0703826.
- H.J. Harwood and T.B. Johnson, J. Am. Chem. Soc., 55, 2555 (1933); doi:10.1021/ja01333a054.
- P. Roszkowski, J.K. Maurin and Z. Czarnocki, Tetrahedron Asymm., 17, 1415 (2006); doi:10.1016/j.tetasy.2006.04.023.
- N.J. Leonard and G.W. Leubner, J. Am. Chem. Soc., 71, 3405 (1949); doi:10.1021/ja01178a039.
References
J. Dingemanse, G. Zürcher and R. Kettler, Eur. J. Pharm. Sci., 12, 159 (2000); doi:10.1016/S0928-0987(00)00151-2.
C. Binda, F. Hubálek, M. Li, D.E. Edmondson and A. Mattevi, FEBS Lett., 564, 225 (2004); doi:10.1016/S0014-5793(04)00209-1.
J.C. Shih, K. Chen and M.J. Ridd, Ann. Rev. Neurosci., 22, 197 (1999); doi:10.1146/annurev.neuro.22.1.197.
D.J. Moore, A.B. West, V.L. Dawson and T.M. Dawson, Ann. Rev. Neurosci., 28, 57 (2005); doi:10.1146/annurev.neuro.28.061604.135718.
M. Bembenek, C.W. Abell, L.A. Chrisey, M.D. Rozwadowska, W. Gessner and A. Brossi, J. Med. Chem., 33, 147 (1990); doi:10.1021/jm00163a025.
M.B.H. Youdim, A. Gross and J.P.M. Finberg, Br. J. Pharmacol., 132, 500 (2001); doi:10.1038/sj.bjp.0703826.
H.J. Harwood and T.B. Johnson, J. Am. Chem. Soc., 55, 2555 (1933); doi:10.1021/ja01333a054.
P. Roszkowski, J.K. Maurin and Z. Czarnocki, Tetrahedron Asymm., 17, 1415 (2006); doi:10.1016/j.tetasy.2006.04.023.
N.J. Leonard and G.W. Leubner, J. Am. Chem. Soc., 71, 3405 (1949); doi:10.1021/ja01178a039.